Dimerix Management

Management criteria checks 2/4

Dimerix's CEO is Nina Webster, appointed in Aug 2018, has a tenure of 6.25 years. total yearly compensation is A$759.06K, comprised of 49.1% salary and 50.9% bonuses, including company stock and options. directly owns 0.073% of the company’s shares, worth A$141.18K. The average tenure of the management team and the board of directors is 3.5 years and 7.1 years respectively.

Key information

Nina Webster

Chief executive officer

AU$759.1k

Total compensation

CEO salary percentage	49.1%
CEO tenure	6.3yrs
CEO ownership	0.07%
Management average tenure	3.5yrs
Board average tenure	7.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nina Webster's remuneration changed compared to Dimerix's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$759k	AU$373k	-AU$17m
Mar 31 2024	n/a	n/a	-AU$14m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$12m
Jun 30 2023	AU$387k	AU$350k	-AU$14m
Mar 31 2023	n/a	n/a	-AU$14m
Dec 31 2022	n/a	n/a	-AU$14m
Sep 30 2022	n/a	n/a	-AU$12m
Jun 30 2022	AU$517k	AU$341k	-AU$10m
Mar 31 2022	n/a	n/a	-AU$10m
Dec 31 2021	n/a	n/a	-AU$9m
Sep 30 2021	n/a	n/a	-AU$7m
Jun 30 2021	AU$408k	AU$334k	-AU$6m
Mar 31 2021	n/a	n/a	-AU$6m
Dec 31 2020	n/a	n/a	-AU$6m
Sep 30 2020	n/a	n/a	-AU$5m
Jun 30 2020	AU$539k	AU$304k	-AU$4m
Mar 31 2020	n/a	n/a	-AU$4m
Dec 31 2019	n/a	n/a	-AU$4m
Sep 30 2019	n/a	n/a	-AU$4m
Jun 30 2019	AU$486k	AU$221k	-AU$3m

Compensation vs Market: Nina's total compensation ($USD493.28K) is above average for companies of similar size in the Australian market ($USD297.98K).

Compensation vs Earnings: Nina's compensation has increased whilst the company is unprofitable.

CEO

Nina Webster

6.3yrs

Tenure

AU$759,063

Compensation

Dr. Nina Webster, Ph D., BSc (Hons), M IP Law, MBA, has been Chief Executive Offer, Managing Director and Director of Dimerix Limited since August 27, 2018. Dr. Webster served as the Commercial Director of...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Nina Webster	CEO, MD & Director	6.3yrs	AU$759.06k	0.073% A$ 141.2k
David Fuller	Chief Medical Officer	1.1yrs	AU$361.30k	0.0033% A$ 6.3k
Robert Shepherd	Chief Commercialisation Officer	less than a year	AU$372.79k	no data
Hamish George	CFO & Company Secretary	5.8yrs	no data	no data
Kevin Pfleger	Chief Scientific Advisor	no data	no data	no data

3.5yrs

Average Tenure

Experienced Management: DXB's management team is considered experienced (3.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Nina Webster	CEO, MD & Director	6.3yrs	AU$759.06k	0.073% A$ 141.2k
Mark Diamond	Non-Executive Chairman	less than a year	AU$52.50k	no data
Hugh Alsop	Independent Non-Executive Director	7.5yrs	AU$60.00k	no data
Sonia Poli	Non Executive Director	9.3yrs	AU$60.00k	0.10% A$ 193.1k
Alessia Fornoni	Member of Medical Advisory Board	7.1yrs	no data	no data
David Power	Member of Medical Advisory Board	7.1yrs	no data	no data
Daniel Cattran	Member of Medical Advisory Board	7.1yrs	no data	no data
Jonathan Hogan	Member of Medical Advisory Board	7.1yrs	no data	no data
Clinton Snow	Non-Executive Director	1.5yrs	AU$60.00k	no data
Laura Mariani	Member of ACTION3 Medical Advisory Board	less than a year	no data	no data

7.1yrs

Average Tenure

Experienced Board: DXB's board of directors are considered experienced (7.1 years average tenure).

Dimerix Management

Management criteria checks 2/4

Key information

Recent management updates

Dimerix Limited Appoints Laura Mariani to Medical Advisory Board

Dimerix Limited, Annual General Meeting, Oct 01, 2024

Dimerix Limited Announces Appointment of Mark Diamond as Director

Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer

Dimerix Limited, Annual General Meeting, Nov 21, 2023

Less than half of directors are independent

Recent updates

Dimerix Limited Appoints Laura Mariani to Medical Advisory Board

New major risk - Revenue size

Dimerix Limited, Annual General Meeting, Oct 01, 2024

New major risk - Shareholder dilution

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Now 34% overvalued after recent price rise

Dimerix Limited Announces Appointment of Mark Diamond as Director

Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer

Dimerix Limited, Annual General Meeting, Nov 21, 2023

New minor risk - Financial data availability

New minor risk - Shareholder dilution

First half 2023 earnings released: AU$0.03 loss per share (vs AU$0.024 loss in 1H 2022)

Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial

Dimerix Limited Announces That FDA Confirms Inclusion of Paediatrics in Action3 Study of DMX-200 for FSGS

Dimerix Limited Announces Clarity 2.0 Covid-19 Study Outcome

Less than half of directors are independent

Dimerix Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2021)

Dimerix Limited Confirms CLARITY 2.0 Led Study of COVID-19 Patients

Dimerix Limited Announces New Patent Family Application for DMX-700

Dimerix Limited Announces DMX-700 Study Shows Significant 80% Reduction in Lung Injury

Dimerix Limited Confirms REMAP-CAP Covid-19 Study Analysis Update

Dimerix Limited Announces New Clinical Trial for DMX-200 in Diabetic Kidney Disease

Dimerix Limited Announces the Recruitment of the First Patient to Its DMX-200 Phase 3 Trial in Patients with FSGS Kidney Disease

Dimerix Limited Announces Approval of Action3 Phase 3 Clinical Trial of DMX-200 in FSGS

Less than half of directors are independent

Dimerix Limited Announces DSMB Change to REMAP-CAP COVID-19 Study

Dimerix Limited Appoints Dr. Ash Soman as Chief Medical Officer

Dimerix Limited Announces Receipt of the First Regulatory Approval in Europe (For Denmark) for Its Pivotal Phase 3 Clinical Trial, Action3

Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study

Insider recently bought AU$512k worth of stock

Dimerix Limited Recommends DMX-200 Clinical Study in COVID-19 Patients

Dimerix Receives Innovation Passport and ILAP Designation

Dimerix Limited Confirms Phase 3 FSGS Kidney Disease Study Design with EMA

Dimerix Limited Confirms Active Discussions with the FDA on the Phase 3 Study Design in Focal Segmental Glomerulosclerosis

Dimerix Limited Updates of DMX-200 Study in COVID-19 Patients in India

Dimerix Limited Provides an Update on the Clarity 2.0 Study in Patients with COVID-19

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.02 loss in 1H 2020)

Dimerix Limited Plans for Next Study in Diabetic Kidney Disease

New 90-day high: AU$0.29

New 90-day low: AU$0.21

Dimerix Limited Announces Acute Respiratory Distress Syndrome in COVID-19 Patients Protocol Published

Dimerix Limited Announces Additional Positive in Vitro Data to Support Further Development of Its Drug Candidate DMX-700 to Treat Chronic Obstructive Pulmonary Disease

New 90-day low - AU$0.28

Full year earnings released - AU$0.026 loss per share

New 90-day high - AU$0.64

New 90-day high - AU$0.45

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure